Abstract:Abstract Gene editing is now routine in all prokaryotic and metazoan cells but has not received much attention in immune cells when the CRISPR-Cas9 technology was introduced in the field of mammalian cell biology less than ten years ago. This versatile technology has been successfully adapted for gene modifications in human myeloid cells and T cells, among others, but applications to human primary B cells have been scarce and limited to activated B cells. This limitation has precluded conclusive studies into cell activation, differentiation or cell cycle control in this cell type. We report on highly efficient, simple and rapid genome engineering in primary resting human B cells using nucleofection of Cas9 ribonucleoprotein complexes. We provide proof-of-principle of gene editing in quiescent human B cells using two model genes: CD46 and CDKN2A . The latter encodes the cell cycle regulator p16 INK4a which is an important target of Epstein-Barr virus (EBV). Infection of B cells carrying a knockout of CDKN2A with wildtype and EBNA3 oncoprotein mutant strains of EBV allowed us to conclude that EBNA3C controls CDKN2A , the only barrier to B cell proliferation in EBV infected cells. Together, this approach enables efficient targeting of specific gene loci in quiescent human B cells supporting basic research as well as immunotherapeutic strategies. Author summary Human hematopoietic stem cells and their derivatives of the myeloid and lymphoid lineages are important targets for gene correction or modifications using the CRISPR-Cas9 technology. Among others, this approach can support site-specific insertion of chimeric antigen receptors (CARs) or T cell receptors (TCRs) into primary T cells. Their subsequent adoptive transfer to patient donors is a promising immunotherapeutic concept that may control chronic infection or certain types of cancer. Human B cells have a similar potential but, in contrast to T cells, they are very sensitive, difficult to handle, and short-lived ex vivo precluding their genetic modification. Here, we provide means to manipulate primary human B cells genetically using in vitro assembled Cas9 ribonucleoprotein complexes and electroporation for their delivery. Our study demonstrates near-to-complete loss of a model target gene and provides examples to evaluate a cellular gene with a critical role during infection with Epstein-Barr virus (EBV).

Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells

Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells

Epigenetic profiles guide improved CRISPR/Cas9-mediated gene knockout in human T cells

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Lipid Nanoparticle-Mediated Gene Editing of Human Primary T Cells and Off-Target Analysis of the CRISPR-Cas9 Indels

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells

Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells

Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells.

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

Highly Efficient Homology-Driven Genome Editing in Human T Cells by Combining Zinc-Finger Nuclease Mrna and AAV6 Donor Delivery.

Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection

Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy

The CRISPR-Cas12a Platform for Accurate Genome Editing, Gene Disruption, and Efficient Transgene Integration in Human Immune Cells

Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

CRISPR/Cas9 Ribonucleoprotein (RNP) Complex Enables Higher Viability of Transfected Cells in Genome Editing of Acute Myeloid Cells

CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy

AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9